ECSP034838A - IMMUNOCONJUGADOS OF THE CD44 CITOTOXIC ANTIBODY - Google Patents

IMMUNOCONJUGADOS OF THE CD44 CITOTOXIC ANTIBODY

Info

Publication number
ECSP034838A
ECSP034838A EC2003004838A ECSP034838A ECSP034838A EC SP034838 A ECSP034838 A EC SP034838A EC 2003004838 A EC2003004838 A EC 2003004838A EC SP034838 A ECSP034838 A EC SP034838A EC SP034838 A ECSP034838 A EC SP034838A
Authority
EC
Ecuador
Prior art keywords
antibody
conjugates
maitansinoid
immunoconjugados
citotoxic
Prior art date
Application number
EC2003004838A
Other languages
Spanish (es)
Inventor
Elinborg Ostermann
Guenther Adolf
Erik Patzelt
Marlies Sproll
Karl-Heinz Heider
John J Miglietta
Dongen Augustinus Antonius Van
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of ECSP034838A publication Critical patent/ECSP034838A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención relacionada con conjugados novedosos de anticuerpos con compuestos citotóxicos, composiciones farmacéuticas conteniendo dichos conjugados y sus usos en la terapia para el cáncer. En particular, la presente invención relaciona a conjugados de anticuerpos que son específicos para CD44 con maitansinoide, preferentemente con N2 -deacetil- N2 (3-mercapto-1-oxopropil)-maitansina (DM1). En la incorporación particular preferida, los conjugados de anticuerpos/maitansinoide pueden ser preparados de un maitansinoide de la fórmula (II) donde R1 representa H o SR4 donde R4 representa metil, eti, alquil linear, alquil ramificado, alquil ciclic, aril sustituido o simple o heterociclic; R2 representa CI o H; R3 representa H o CH3; y m representa 1, 2 o 3. Preferentemente R1 es H o CH3, R2 es CI, R3 es CH3 y m=2. Los compuestos con R1 = H, R2 = CI, R3= CH3 y m=2 está designado DMI en la literaturaThe present invention related to novel antibody conjugates with cytotoxic compounds, pharmaceutical compositions containing said conjugates and their uses in cancer therapy. In particular, the present invention relates to antibody conjugates that are specific for CD44 with maitansinoid, preferably with N2 -deacetyl-N2 (3-mercapto-1-oxopropyl) -maitansin (DM1). In the particular preferred embodiment, the antibody / maitansinoid conjugates can be prepared from a maitansinoid of the formula (II) where R1 represents H or SR4 where R4 represents methyl, eti, linear alkyl, branched alkyl, cyclic alkyl, substituted or simple aryl or heterocyclic; R2 represents CI or H; R3 represents H or CH3; and m represents 1, 2 or 3. Preferably R1 is H or CH3, R2 is CI, R3 is CH3 and m = 2. Compounds with R1 = H, R2 = CI, R3 = CH3 and m = 2 is designated DMI in the literature

EC2003004838A 2001-05-18 2003-11-10 IMMUNOCONJUGADOS OF THE CD44 CITOTOXIC ANTIBODY ECSP034838A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01112237 2001-05-18

Publications (1)

Publication Number Publication Date
ECSP034838A true ECSP034838A (en) 2003-12-24

Family

ID=33442672

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004838A ECSP034838A (en) 2001-05-18 2003-11-10 IMMUNOCONJUGADOS OF THE CD44 CITOTOXIC ANTIBODY

Country Status (18)

Country Link
EP (1) EP1397387A1 (en)
JP (1) JP2005504517A (en)
CN (1) CN1541226A (en)
AR (1) AR036154A1 (en)
BR (1) BR0210905A (en)
CA (1) CA2443437A1 (en)
CZ (1) CZ20033476A3 (en)
EA (1) EA200301169A1 (en)
EC (1) ECSP034838A (en)
EE (1) EE200300569A (en)
HU (1) HUP0400030A3 (en)
MX (1) MXPA03010523A (en)
PE (1) PE20021098A1 (en)
PL (1) PL365735A1 (en)
SK (1) SK15592003A3 (en)
WO (1) WO2002094879A1 (en)
YU (1) YU91403A (en)
ZA (1) ZA200307365B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
EP1861425B1 (en) 2005-03-10 2012-05-16 Morphotek, Inc. Anti-mesothelin antibodies
AU2006241099B2 (en) 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EP2167038B1 (en) * 2007-06-13 2018-04-25 Zymogenetics, Inc. Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
EP2531527B1 (en) 2010-02-04 2014-03-19 F.Hoffmann-La Roche Ag A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma
CN102337298B (en) * 2011-08-19 2013-11-06 黄开红 Immune nano-carrier for conveying siRNA (small interfering Ribonucleic Acid) and preparation method and application thereof
US20140335084A1 (en) 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
WO2017215637A1 (en) * 2016-06-15 2017-12-21 李翀 Human endometrial cancer marker, antibody, and application of antibody
CN107556388A (en) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 The double targeting antibodies of anti-CD44v6 and CD3 specificity, the minicircle dna containing this pair of targeting antibodies expression cassette and application
WO2021178896A1 (en) * 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
WO2022187591A1 (en) * 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
EP0672130A1 (en) * 1992-11-20 1995-09-20 Isis Innovation Limited Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
UA58482C2 (en) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх MONOCLONAL ANTIBODY VFF-18 AGAINST CD44V6 AND ITS FRAGMENTS
UY24389A1 (en) * 1995-12-06 2001-10-25 Karlsruhe Forschzent PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FLAT EPITHELIUM CARCINOMA

Also Published As

Publication number Publication date
YU91403A (en) 2006-05-25
HUP0400030A2 (en) 2004-04-28
WO2002094879A1 (en) 2002-11-28
BR0210905A (en) 2004-06-08
JP2005504517A (en) 2005-02-17
CN1541226A (en) 2004-10-27
SK15592003A3 (en) 2004-06-08
ZA200307365B (en) 2004-05-10
CA2443437A1 (en) 2002-11-28
HUP0400030A3 (en) 2006-02-28
PE20021098A1 (en) 2003-02-11
PL365735A1 (en) 2005-01-10
AR036154A1 (en) 2004-08-18
EE200300569A (en) 2004-04-15
EA200301169A1 (en) 2004-06-24
EP1397387A1 (en) 2004-03-17
MXPA03010523A (en) 2004-07-01
CZ20033476A3 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
ECSP034838A (en) IMMUNOCONJUGADOS OF THE CD44 CITOTOXIC ANTIBODY
ES2169147T3 (en) DERIVATIVES OF BETA-CARBOLINA AGONISTAS DE MELATONINA, ITS PREPARATION PROCEDURES AND ITS USE BY A MEDICINAL TITLE.
AR018634A1 (en) BENZO DERIVATIVES (B) TIEPIN-1,1, -DIOXIDE, PROCEDURE FOR PREPARATION, MEDICATIONS CONTAINING THESE COMPOUNDS, PROCEDURE FOR PREPARATION OF MEDICINES AND THEIR EMPLOYMENT FOR PREPARATION OF MEDICINES.
MX9300498A (en) DERIVATIVES OF N-SULFONIL-2-OXO-INDOL, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
AR012315A1 (en) DERIVATIVES OF DITIOLAN AND THE USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT.
AR033499A1 (en) DERIVED FROM QUINAZOLINE, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE IN THE MANUFACTURE OF MEDICINES TO USE IN THE PRODUCTION OF AN ANANGEOGENIC EFFECT AND / OR REDUCER OF VASCULAR PERMEABILITY IN A HOT BLOOD ANIMAL
ES2054860T5 (en) DERIVATIVES OF 9-HALOGEN- (Z) -PROSTAGLANDINAS, PROCEDURE FOR ITS PREPARATION AND ITS USE AS MEDICATIONS.
ECSP066667A (en) SPIROCICLIC CYCLHEXAN DERIVATIVES
ES2071510T3 (en) DERIVATIVES OF PIRROLIDINE AND THIAZOLIDINE, THEIR PREPARATION AND THE MEDICINES CONTAINING THEM.
AR065937A2 (en) INDAZOL DERIVATIVE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE IN THE MANUFACTURE OF MEDICINES TO MODULATE THE ACTIVITY OF PROTEIN KINASE
ES2113867T3 (en) CYCLIC IMINO-DERIVATIVES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCEDURE FOR THEIR PREPARATION.
ES2176480T3 (en) ACILATED DERIVATIVES OF MELATONIN AND ANALOGS AS MEDICINES.
MXPA03010432A (en) Cytotoxic cd44 antibody immunoconjugates.
MX9305769A (en) NEW DERIVATIVES OF ANALOGS OF TAXOL, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ECSP034831A (en) SUBSTITUTED DERIVATIVES OF 2-PYRIDINE CYCLHEXAN-1,4-DIAMINE
SV1999000118A (en) NEW SUBSTITUTED PIRAZOL DERIVATIVES REF. READ 33188-SV
CO5590895A2 (en) DERIVATIVES OF SULFONAMIDS, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS
ES2093732T3 (en) NEW DERIVATIVES OF ERUCILO, BRASIDILO AND NERVONILO.
IT1173374B (en) PYRID-BENZOTHIAZINIC DERIVATIVES WITH HIGH ANTIMICROBIAL ACTIVITY
ES2115904T3 (en) RAMIFIED AMINO DERIVATIVES OF TIAZOL, ITS PREPARATION PROCEDURES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2122637T3 (en) DERIVATIVES OF THIAZOLIDINE, ITS PREPARATION AND THE MEDICINES THAT CONTAIN THEM.
AR043487A1 (en) FUSIONED HEREROCICLES OF PYRIMIDINE AND USES OF THE SAME
ES2062706T3 (en) NEW DERIVATIVES OF AMINO-METHYL-PIPERIDINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
CO5040004A1 (en) 2-4-DIAMINO-1,3,5-TRIAZINAS, ITS PREPARATION AND EMPLOYMENT AS HERBICIDES AND PHYTO-REGULATORS
ES2083625T3 (en) DERIVATIVES OF N-FENILTIOUREA AND PHARMACEUTICAL USE THEREOF.